Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 3Sarcoma 1Plasma cell 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Immunoblastic Lymphadenopathy 1Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × enasidenib × Sarcoma × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡